Novartis and Sandoz partner with Biocon on biosimilar development

Pharmaceutical Company Product News

Novartis and Sandoz has announced a new collaboration with Biocon on the development of new biosimilar therapies.

Under the terms of the deal, the companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for multiple biosimilars in immunology and oncology for patients worldwide.

“Novartis and Sandoz are partnering with Biocon to develop, manufacture and commercialise multiple biosimilars for immunology and oncology applications.“

A global cost and profit sharing arrangement has been agreed, with worldwide commercialisation responsibilities to be divided and each company's strengths leveraged within specific geographies.

Sandoz will lead the work in North America and the EU, while Biocon will handle the rest of the world.

Biocon has successfully developed and taken a range of novel biologics, biosimilar antibodies, rh-insulin and insulin analogs from lab to market, with this new collaboration building on Biocon's successful progress in its existing global biosimilars programme.

Richard Francis, chief executive officer at Sandoz, said: "Biocon is a great complement to our proven biosimilar capabilities at Sandoz. Through this collaboration, we are reinforcing our long-term commitment to increase patient access to biologics."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news